ARCHIVES

FDA Told To Drop Guidelines, But Remains Unmoved On New Drug Delays

This article is from The Cancer Letter archive.

Vol. 01 No. 49 | December 5, 1975

Download PDF Visit The Full Archive

Related Articles

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

March 31, 2000

NAB Report To President Makes Pitch for Money, Cites Research Progress

August 9, 1974

Cancer Policy: President’s Cancer Panel Issues Statement On National Cancer Program

September 17, 1999

US Oncology To Participate In Firm’s Ovarian Cancer Trial.

January 26, 2001

PET Response Can Predict Increased Survival In Patients

April 27, 2012

Howard Hughes Medical Institute Appoints 12 Physician Investigators

May 31, 2002